Publicacions en col·laboració amb investigadors/es de Pfizer (United States) (14)

2024

  1. Antibiotic resistance and tolerance: What can drug delivery do against this global threat?

    Drug Delivery and Translational Research, Vol. 14, Núm. 6, pp. 1725-1734

2023

  1. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

    Cell, Vol. 186, Núm. 12, pp. 2628-2643.e21

2021

  1. Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 5, pp. 967-973

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain

    Clinical Rheumatology, Vol. 39, Núm. 10, pp. 2919-2930

2019

  1. Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

    ClinicoEconomics and Outcomes Research, Vol. 11, pp. 465-475

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2009

  1. A global benchmark study using affinity-based biosensors

    Analytical Biochemistry, Vol. 386, Núm. 2, pp. 194-216

2008

  1. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial

    Clinical Microbiology and Infection, Vol. 14, Núm. 4, pp. 307-314

2006

  1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

    Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69

2005

  1. HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells

    Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475

  2. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58